Floatz logo

Setmelanotide

Obesity Due to Melanocortin 4 Receptor Deficiency

Rhythm Pharmaceuticals, Inc.protein_peptidePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Obesity Due to Melanocortin 4 Receptor Deficiency cohort.

Asset / SponsorPhaseRating
Strattera
Icahn School of Medicine at Mount Sinai
Phase 2NR

Same molecule, other indications

Setmelanotide is also rated in:

Bardet-Biedl syndromeDormant
A
Indicative ·
81 / 100
View asset →
Alstrom syndromeDormant
BBB
Indicative ·
75 / 100
View asset →
inherited obesityDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →